Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with migraine according to a recognised international diagnostic standard (called ICHD-III)
- People for whom a doctor has prescribed one of the following medicines for migraine: erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant, or rimegepant — with the prescription meeting local rules and reimbursement requirements
- People who have signed a consent form agreeing to take part in the study
Who may not be able to join:
- People who have a type of headache that is not migraine
- People who have a serious active psychiatric condition or significant memory or thinking difficulties that could affect their ability to give informed consent to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Patricia Pozo-Rosich, MD, PhD, Vall d'Hebron University Hospital
Phone: (+34) 93 489 30 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Monthly Headache Days and Monthly Migraine Days
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.